InsiderTrades.com logo
Gregory L. Weaver net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Gregory Weaver Biography and Net Worth

CFO of Altimmune

Mr. Weaver joined Altimmune as Chief Financial Officer in November 2024. He has over 25 years of finance experience across a range of publicly-traded and privately-held life sciences companies. Most recently, he was CFO of Cognito Therapeutics, a clinical-stage company targeting neurodegenerative diseases. Prior to joining Cognito, he was CFO at atai Life Sciences (Nasdaq: ATAI), a neuropsychiatry company where he led a $225 million Initial Public Offering in 2021. Throughout his career, Mr. Weaver has led multiple capital markets transactions, manufacturing and R&D investments, product launches and M&A transactions.

He has led the finance, SEC reporting and investor relations functions as CFO of multiple publicly-traded biotech companies including Sirna Therapeutics (Nasdaq: RNAI), a genetic medicines company acquired by Merck and ILEX Oncology (Nasdaq: ILXO), a commercial-stage company acquired by Genzyme.

He currently serves as a Director and Chair of the Audit Committee at BioIntelliSense, a commercial-stage patient monitoring technology company and as Vice-Chairman of the Board at HarborPath, a non-profit organization focused on providing patients with access to life-saving medications. A United States Air Force veteran, he holds a bachelor’s degree in Accounting and Finance from Trinity University and an MBA from Boston College.

What is Gregory L. Weaver's net worth?

The estimated net worth of Gregory L. Weaver is at least $53.10 thousand as of March 13th, 2025. Mr. Weaver owns 10,000 shares of Altimmune stock worth more than $53,100 as of December 5th. This net worth estimate does not reflect any other assets that Mr. Weaver may own. Learn More about Gregory L. Weaver's net worth.

How do I contact Gregory L. Weaver?

The corporate mailing address for Mr. Weaver and other Altimmune executives is 910 CLOPPER ROAD SUITE 201S, GAITHERSBURG MD, 20878. Altimmune can also be reached via phone at (240) 654-1450 and via email at [email protected]. Learn More on Gregory L. Weaver's contact information.

Has Gregory L. Weaver been buying or selling shares of Altimmune?

Gregory L. Weaver has not been actively trading shares of Altimmune in the last ninety days. Most recently, on Thursday, March 13th, Gregory L. Weaver bought 10,000 shares of Altimmune stock. The stock was acquired at an average cost of $5.20 per share, with a total value of $52,000.00. Following the completion of the transaction, the chief financial officer now directly owns 10,000 shares of the company's stock, valued at $52,000. Learn More on Gregory L. Weaver's trading history.

Who are Altimmune's active insiders?

Altimmune's insider roster includes Matthew Harris (Insider), and Gregory Weaver (CFO). Learn More on Altimmune's active insiders.

Are insiders buying or selling shares of Altimmune?

During the last twelve months, Altimmune insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $52,000.00. The most recent insider tranaction occured on March, 13th when CFO Gregory L Weaver bought 10,000 shares worth more than $52,000.00. Insiders at Altimmune own 4.4% of the company. Learn More about insider trades at Altimmune.

Information on this page was last updated on 3/13/2025.

Gregory L. Weaver Insider Trading History at Altimmune

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/13/2025Buy10,000$5.20$52,000.0010,000View SEC Filing Icon  
See Full Table

Gregory L. Weaver Buying and Selling Activity at Altimmune

This chart shows Gregory L Weaver's buying and selling at Altimmune by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Altimmune Company Overview

Altimmune logo
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Read More

Today's Range

Now: $5.31
Low: $5.00
High: $5.46

50 Day Range

MA: $4.24
Low: $3.75
High: $5.31

2 Week Range

Now: $5.31
Low: $2.90
High: $10.11

Volume

3,102,451 shs

Average Volume

3,239,259 shs

Market Capitalization

$554.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A